NRX Pharmaceuticals Inc. (NASDAQ: NRXP)
$2.54
+0.1500 ( +6.28% ) 95.8K
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Market Data
Open
$2.54
Previous close
$2.39
Volume
95.8K
Market cap
$26.75M
Day range
$2.37 - $2.54
52 week range
$1.90 - $7.33
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 16 | Apr 02, 2024 |
10-k | Annual reports | 98 | Mar 29, 2024 |
8-k | 8K-related | 16 | Mar 28, 2024 |
8-k | 8K-related | 15 | Mar 21, 2024 |
def | Proxies and info statements | 4 | Mar 11, 2024 |
8-k | 8K-related | 18 | Mar 06, 2024 |
8-k | 8K-related | 24 | Feb 28, 2024 |
8-k | 8K-related | 16 | Feb 14, 2024 |
8-k | 8K-related | 16 | Feb 14, 2024 |
8-k | 8K-related | 15 | Feb 02, 2024 |